13.82
price up icon0.14%   0.02
after-market Dopo l'orario di chiusura: 13.83 0.010 +0.07%
loading
Precedente Chiudi:
$13.80
Aprire:
$13.76
Volume 24 ore:
974.22K
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.72B
Reddito:
$181.74M
Utile/perdita netta:
$-599.49M
Rapporto P/E:
-2.7585
EPS:
-5.01
Flusso di cassa netto:
$-604.32M
1 W Prestazione:
-6.62%
1M Prestazione:
-27.03%
6M Prestazione:
-29.74%
1 anno Prestazione:
-51.68%
Intervallo 1D:
Value
$13.66
$13.99
Intervallo di 1 settimana:
Value
$13.66
$15.65
Portata 52W:
Value
$13.66
$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Nome
Arrowhead Pharmaceuticals Inc
Name
Telefono
626-696-4702
Name
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Name
Dipendente
525
Name
Cinguettio
@ArrowheadPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
ARWR's Discussions on Twitter

Confronta ARWR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARWR
Arrowhead Pharmaceuticals Inc
13.82 1.72B 181.74M -599.49M -604.32M -5.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-06-05 Iniziato Goldman Neutral
2023-12-04 Iniziato BofA Securities Buy
2023-09-19 Iniziato Citigroup Neutral
2023-07-21 Iniziato TD Cowen Outperform
2023-05-12 Downgrade SVB Securities Outperform → Market Perform
2023-04-26 Iniziato SMBC Nikko Outperform
2023-04-12 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-21 Iniziato Bernstein Mkt Perform
2022-09-09 Iniziato Morgan Stanley Equal-Weight
2022-05-11 Aggiornamento Robert W. Baird Neutral → Outperform
2022-01-19 Ripresa Goldman Buy
2021-08-06 Reiterato Chardan Capital Markets Buy
2021-06-04 Ripresa Robert W. Baird Neutral
2021-02-05 Reiterato H.C. Wainwright Buy
2020-12-21 Downgrade Robert W. Baird Outperform → Neutral
2020-12-16 Iniziato UBS Buy
2020-11-19 Iniziato Citigroup Buy
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-05-08 Aggiornamento Oppenheimer Perform → Outperform
2020-04-15 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-03-24 Aggiornamento SVB Leerink Underperform → Mkt Perform
2020-03-17 Iniziato Goldman Neutral
2020-01-21 Iniziato SVB Leerink Underperform
2019-12-13 Iniziato Oppenheimer Perform
2019-11-29 Reiterato Chardan Capital Markets Buy
2019-11-27 Reiterato B. Riley FBR Buy
2019-11-25 Aggiornamento Robert W. Baird Neutral → Outperform
2019-10-24 Downgrade Robert W. Baird Outperform → Neutral
2019-10-22 Reiterato Chardan Capital Markets Buy
2019-10-03 Iniziato Robert W. Baird Outperform
2018-09-07 Aggiornamento B. Riley FBR Neutral → Buy
2018-09-06 Reiterato Chardan Capital Markets Buy
2018-08-08 Reiterato Cantor Fitzgerald Overweight
2018-07-02 Reiterato Chardan Capital Markets Buy
Mostra tutto

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

pulisher
Mar 27, 2025

Rnai Technology Market Set to Witness Significant Growth - openPR

Mar 27, 2025
pulisher
Mar 26, 2025

Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Mar 26, 2025
pulisher
Mar 25, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance

Mar 25, 2025
pulisher
Mar 21, 2025

Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 19, 2025

(ARWR) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 19, 2025
pulisher
Mar 17, 2025

RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025
pulisher
Mar 17, 2025

First Capital REIT Announces March 2025 Distribution - The Globe and Mail

Mar 17, 2025
pulisher
Mar 12, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK

Mar 11, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL

Mar 10, 2025
pulisher
Mar 10, 2025

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St

Mar 10, 2025
pulisher
Mar 10, 2025

Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard

Mar 06, 2025
pulisher
Mar 06, 2025

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 05, 2025

Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com

Mar 05, 2025
pulisher
Mar 04, 2025

Familial Chylomicronemia Syndrome Market to Expand - openPR

Mar 04, 2025
pulisher
Mar 04, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World

Mar 04, 2025
pulisher
Mar 02, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Galveston County Daily News

Feb 28, 2025
pulisher
Feb 28, 2025

How Arrowhead's New FCS Resources Could Transform Life for Rare Disease Patients - StockTitan

Feb 28, 2025
pulisher
Feb 26, 2025

Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Objective long/short (ARWR) Report - Stock Traders Daily

Feb 25, 2025
pulisher
Feb 25, 2025

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian

Feb 25, 2025
pulisher
Feb 25, 2025

Can Arrowhead's New Obesity Drug Outperform GLP-1s? Preclinical Data Shows Key Advantage - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Feb 24, 2025
pulisher
Feb 22, 2025

Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 20, 2025
pulisher
Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025
pulisher
Feb 19, 2025

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha

Feb 19, 2025
pulisher
Feb 19, 2025

Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters

Feb 19, 2025
pulisher
Feb 19, 2025

Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa

Feb 19, 2025
pulisher
Feb 18, 2025

Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN

Feb 17, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat

Feb 17, 2025

Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Capitalizzazione:     |  Volume (24 ore):